FUT8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6849679	0.50	3/20
SCHEMBL9333401	0.49	3/20
SCHEMBL9360776	0.48	3/20
SCHEMBL285816	0.47	3/20
SCHEMBL9326023	0.46	3/20
SCHEMBL8055072	0.44	3/20
SCHEMBL10766973	0.44	3/20
SCHEMBL8614949	0.44	3/20
SCHEMBL6297713	0.44	3/20
SCHEMBL11567537	0.44	3/20
SCHEMBL11310040	0.41	3/20
SCHEMBL10589718	0.41	3/20
SCHEMBL11320857	0.40	3/20
SCHEMBL12189981	0.40	3/20
SCHEMBL12463120	0.36	3/20
SCHEMBL4360990	0.81	2/20
Cibacron Blue (SCHEMBL4350042)	0.77	2/20
SCHEMBL9171465	0.74	2/20
SCHEMBL3031205	0.73	2/20
SCHEMBL4409511	0.72	2/20

Clinical trials — most relevant to FUT8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study	PHASE4	COMPLETED
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications	PHASE2	COMPLETED
Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I	PHASE2	COMPLETED
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults	PHASE2	COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388	PHASE2	ACTIVE_NOT_RECRUITING
Cetuximab and Lenalidomide in Head and Neck	PHASE2	COMPLETED
GD2/CD56 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer	PHASE2	RECRUITING
Daratumumab in Combination With ATRA	PHASE1/PHASE2	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I	PHASE1	WITHDRAWN
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects	PHASE1	COMPLETED
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS	PHASE1	RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease	PHASE1	COMPLETED
A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine	PHASE1	ACTIVE_NOT_RECRUITING
The Correlation of Lewis Antigens With VTE	nan	NOT_YET_RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Evaluation of Serum Tumor Endothelial Marker1 as a Potential Biomarker for Colorectal Cancer Diagnosis and Cancer Progression	nan	NOT_YET_RECRUITING
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
The Natural History of Sialidosis Type I	nan	RECRUITING
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid	nan	UNKNOWN
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FUT8 binder may also engage these)

Protein	Name	Similarity
Q6EV77	—	1.000	Q6EV77 →
P79282	—	1.000	P79282 →
Q5NVB3	—	1.000	Q5NVB3 →
Q6EV76	—	1.000	Q6EV76 →
Q659X0	—	1.000	Q659X0 →
Q6NVP8	—	1.000	Q6NVP8 →
Q9WTS2	—	1.000	Q9WTS2 →
Q9N0W2	—	0.998	Q9N0W2 →
Q9ZVF7	—	0.974	Q9ZVF7 →
F1QR43	—	0.969	F1QR43 →
Q6EV70	—	0.969	Q6EV70 →
Q6GMK0	—	0.967	Q6GMK0 →
P83337	—	0.967	P83337 →
Q812G0	—	0.967	Q812G0 →
Q4R854	—	0.965	Q4R854 →
Q9EPS3	—	0.965	Q9EPS3 →
Q91ZW2	—	0.965	Q91ZW2 →
O94923	—	0.964	O94923 →
Q9JHP7	—	0.964	Q9JHP7 →
P79948	—	0.964	P79948 →
Q6EV69	—	0.964	Q6EV69 →
O77836	—	0.963	O77836 →
Q66PG2	—	0.962	Q66PG2 →
Q94EJ6	—	0.962	Q94EJ6 →
Q8IYK4	—	0.961	Q8IYK4 →
CSGALNACT1	Chondroitin sulfate N-acetylgalactosaminyltransferase 1	0.961	landscape →
Q7ZVE6	—	0.961	Q7ZVE6 →
Q6EV56	—	0.961	Q6EV56 →
Q6GQI7	—	0.961	Q6GQI7 →
A1A4K5	—	0.961	A1A4K5 →